NVS - Novartis AG
| Previous Close | 88.58 |
| Open | 88.85 |
| Bid | 89.01 x 900 |
| Ask | 91.50 x 1200 |
| Day's Range | 88.81 - 89.56 |
| 52 Week Range | 72.73 - 95.00 |
| Volume | 1,109,911 |
| Avg. Volume | 2,117,406 |
| Market Cap | 205.572B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 18.38 |
| EPS (TTM) | 4.87 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.83 (3.20%) |
| Ex-Dividend Date | 2019-03-04 |
| 1y Target Est | 101.00 |
- Yahoo Finance Video
Amgen wins U.S. patent battle on arthritis drug Enbrel
A U.S. Judge up-held 2 patents relating to Amgen’s Rheumatoid Arthritis drug Enbrel after they were challenged by competitor Novartis. Yahoo Finance's Scott Gamm joins Akiko Fujita to discuss.
- Motley Fool
A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis
What Novartis' misstep means to investors, plus how Exact Sciences is trying to lock up the genetic testing market.
- Zacks
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
- American City Business Journals
Gene therapies to test FDA's approach to regulating drugs after launch, experts say
"If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.
- American City Business Journals
Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future
The Florida startup has Bay Area investors and is aiming straight at people willing to pay thousands of dollars to beat cancer in the future.
- Zacks
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
Epizyme (EPZM) aims at developing its lead pipeline candidate, tazemetostat, which is under FDA review with an action date of Jan 23, 2020.
- Reuters
Novartis replaces top scientists at Avexis after drug data manipulated
Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.
- Investor's Business Daily
Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data
Swiss pharma giant Novartis reportedly fired two scientists at its AveXis unit for manipulating data necessary to gain approval of gene therapy Zolgensma, CNBC reported Wednesday.
- Reuters
UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated
Novartis AG said on Wednesday it replaced the two top research and development executives at its Avexis unit after some data was manipulated from early testing of a gene therapy for infants that costs more than $2 million. Avexis' Chief Scientific Officer Brian Kaspar and Senior Vice President of Research and Development Allan Kaspar have not been involved in any operations at Avexis since early May 2019, Novartis said in a statement. Brian Kaspar was a founder and key executive at Avexis and made more than $380 million from the company's 2018 acquisition by Novartis, according to SEC filings.
- Barrons.com
Everyone’s Mad At Novartis. But the Stock Is Doing Just Fine
Public pressure is heating up on Novartis A.G. over how the company handled a data manipulation issue, but the stock is doing just fine, thanks.
- Zacks
Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80%
Deciphera's (DCPH) pipeline candidate, ripretinib, improves progression free survival in a pivotal study evaluating it in previously treated, advanced gastrointestinal stromal tumors.
- InvestorPlace
Wednesday’s Vital Data: Amgen, American Airlines and Apple
The topsy-turvy ride for stock traders continues this morning with U.S. stock futures pointing toward a sizeable down gap at the open. Yesterday's gains are being completely unwound.Source: Shutterstock Heading into the open, futures on the Dow Jones Industrial Average are down 1.46%, and S&P 500 futures are lower by 1.42%. Nasdaq-100 futures have lost 1.57%.In the options pits, call volume spiked sharply yesterday underlying the excitement surrounding the market rally. Specifically, about 19.9 million calls and 17.5 million puts changed hands on the session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe enthusiasm was felt at the CBOE as well, with the single-session equity put/call volume ratio falling to 0.66. Meanwhile, the 10-day moving average held its ground at 0.74. Based on the wickedness of today's open, however, I suspect both metrics to end with bearish readings today.Options traders came after calls throughout the session, boosting volumes in Amgen (NYSE:AMGN), American Airlines Group (NYSE:AAL) and Apple (NASDAQ:AAPL).Let's take a closer look: Amgen (AMGN)The direction of Amgen shares reversed in a big way this week after the biotech behemoth won a patent dispute against Novartis (NYSE:NVS). Over the past three sessions, AMGN stock has rocketed 12% higher on massive volume. The rally pushed shares back to last year's highs, and they now stand a whisper from breaking out to record levels. * 15 Growth Stocks to Buy for the Long Haul In the short run, AMGN is extended and deserving of a breather. Consolidation or a pullback will allow its moving averages to catch-up and make for a more sustainable uptrend. That said, any weakness should be viewed as a buying opportunity.On the options trading front, traders went cuckoo for calls. Activity ballooned to 1,314% of the average daily volume, with 275,296 total contracts traded; 96% of the trading came from call options alone. The catalyst for such a groundswell in call demand is the company's looming ex-dividend date. Amgen's next quarterly payment of $1.45 will be paid out to shareholders of record and investors used call options to snatch-up short-term control of the stock to gain access to the payout.Implied volatility has been falling this week and now sits at 24% or the 29th percentile of its one-year range. Premiums are baking in daily moves of $3.08 or 1.5%, so set your expectations accordingly. American Airlines (AAL)The news was light for American Airlines Group, but that didn't prevent traders from swarming its options. In an otherwise ordinary day, we saw options activity jump to 270% of the average daily volume, with 107,237 total contracts traded. Calls slightly outpaced puts to claim 55% of the session's sum.Ever since last month's earnings took the wind out of its sails, AAL stock has been declining. It has now lost 21% in three weeks and will soon test its 52-week low at $27.02. Of course, weakness isn't new for AAL. It has been in a cyclical decline for two years and has already lost over 53% of its value. Until we see resistance levels breached, buyers should cast their lines elsewhere. There are much more attractive fish to catch.Implied volatility remains, tucked near the middle of its 2019 range. It's at 41% or the 31st percentile, and premiums are pricing in daily moves of 71 cents or 2.6%. Apple (AAPL)Apple stock led the charge during Tuesday's roaring rally in the Nasdaq for one simple reason. It dodged Chinese tariffs for this year's iPhones. Here's the skinny if you want all the details.Before we get too excited over yesterday's jump, keep in mind the overnight whacking for stocks is taking a bite out of Apple's gains. The stock is set to open down 2.4%. Time will tell if the positive news is enough to keep AAPL stock aloft while the rest of the market grapples with growing recession concerns. * 7 Stocks the Insiders Are Buying on Sale The post-earnings slide found support at $192.50, so that's the line in the sand to watch. If broken, this year's ascent is in a heap of trouble. Until then, ignore the chop and focus on the bigger picture, which still points higher.On the options trading front, traders favored calls throughout the day. Total activity swelled to 137% of the average daily volume, with 686,707 contracts traded. Calls added 59% to the day's take.With uncertainty easing, implied volatility sunk to 29% or the 35th percentile of its one-year range. That means traders are now pricing in daily movement of $3.87 or 1.9%.As of this writing, Tyler Craig didn't hold a position in any of the aforementioned securities. Check out his recently released Bear Market Survival Guide to learn how to defend your portfolio against market volatility. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post Wednesday's Vital Data: Amgen, American Airlines and Apple appeared first on InvestorPlace.
- Zacks
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study
Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.
- Reuters
Novartis names Bulto as new head of U.S. drugs business
Swiss drugmaker Novartis has named company veteran Victor Bulto as head of its U.S. pharmaceuticals business, effective on Sept. 1. The statement said Chouraqui had "consistently demonstrated strong leadership, ethics and integrity" during his tenure. Bulto, who will report to Marie France Tschudin, global president of Novartis Pharmaceuticals, is a 14-year company veteran who has worked across every therapeutic area at the group and helped launch several products, including top-selling inflammation drug Cosentyx in the U.S. market.
- Financial Times
Novartis ousted scientists before reporting drug data manipulation
The news of the timing of the administrative leave comes after analysts and politicians have raised questions about whether Novartis should have informed the FDA before it approved the drug on May 28. The company waited another month, until it had completed an internal investigation and the drug was approved, to tell the FDA.
- Investor's Business Daily
Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales
Amgen stock is the IBD Stock Of The Day after the biggest biotech company prevailed in a patent battle against Novartis subsidiary Sandoz, protecting nearly $5 billion in 2019 U.S. sales.
- Zacks
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
- Zacks
Here's Why Amgen Stock is Outperforming Its Industry Of Late
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
- Motley Fool
5 Biggest New Drugs Approved in 2019 So Far
And the one big pharma most likely to benefit the most.
- Reuters
UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues
U.S. Senate Finance Committee Chairman Chuck Grassley has asked Swiss drugmaker Novartis AG to provide details on data manipulation related to its $2 million gene therapy, Zolgensma, by Aug. 23. The Republican, in a letter dated Aug.9 to the drugmaker's Chief Executive Officer Vasant Narasimhan, asked the company to provide all records on its internal inquiry into Zolgensma data discrepancies. Grassley wanted Novartis to submit additional details, including the date when it came to know that it issued manipulated data to the FDA as well as the number of employees terminated in relation to the issue.
- Reuters
Senator Grassley seeks info on Novartis's Zolgensma data issues
U.S. Senate Finance Committee Chairman Chuck Grassley has sought more information from Swiss drugmaker Novartis AG on the reasons for "intentional withholding" of data related to its $2 million gene therapy, Zolgensma, by Aug. 23. In a letter dated Aug.9 to the drugmaker's Chief Executive Officer Vasant Narasimhan, Republican Grassley asked the company to provide all records on its internal inquiry into Zolgensma data manipulation https://www.grassley.senate.gov/sites/default/files/constituents/2019-08-09%20CEG%20to%20Novartis%20(Misconduct).pdf. The drugmaker had last week said it knew about the discrepancies in data it submitted to regulators while it sought approval of its gene therapy, but delayed notifying authorities until it has completed an internal investigation.
- Investor's Business Daily
The Biggest Biotech Stock Is Approaching A Breakout — Here's Why
Amgen stock continued a two-day run Monday and approached a buy point after a judge upheld two key patents protecting the biotech company's blockbuster drug Enbrel against a Sandoz copycat.
